ArticleJournal of clinical laboratory analysis2020
Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Associations between Serum Interleukins (IL-1BioMed research international · 2022Pooled it
- Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Nervous system diseases are associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis.Epidemiology and infection · 2021Pooled it
- Investigation of the correlation between serum levels of interleukin-6 and clinical and paraclinical findings in COVID-19 patients.Current therapeutic research, clinical and experimental · 2026Article
- The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 (COVID-19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill.Journal of clinical laboratory analysis · 2026Article
- Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.Current medicinal chemistry · 2025Article
- IL-6 and SAA-Strong Predictors for the Outcome in COVID-19 CKD Patients.International journal of molecular sciences · 2023Article
- The utility of serum amyloid A and other acute-phase reactants determination in ambulatory care COVID-19 patients.Journal of medical biochemistry · 2023Article
- Serum Amyloid A Levels and Severity of COVID-19 in Children.Indian pediatrics · 2023Article
- Serum amyloid A-A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19.Frontiers in medicine · 2023Review
- C-Reactive Protein (CRP): A Potent Inflammation Biomarker in Psychiatric Disorders.Advances in experimental medicine and biology · 2023Article
- "Lymphocyte * Neutrophil" count decreased in SARS-CoV-2 Omicron patients in Shanghai with no significant change in CRP and SAA.Journal of clinical laboratory analysis · 2022Article
- Comparison of laboratory parameters in mildJournal of thoracic disease · 2022Article
- The Association between TNF-α, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Review
- Biomarkers of Post-COVID Depression.Journal of clinical medicine · 2021Review
- Low serum level of apolipoprotein A1 may predict the severity of COVID-19: A retrospective study.Journal of clinical laboratory analysis · 2021Article
- Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis.International immunopharmacology · 2021Article
- Circulating Calprotectin as a Biomarker of COVID-19 Severity.Expert review of clinical immunology · 2021Review
- Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSerum amyloid A (SAA), interleukin-6 (IL-6) and neutrophil-to-lymphocyte ratio (NLR) play critical roles in inflammation and are used in clinical laboratories as indicators of inflammation-related diseases. We aimed to provide potential laboratory basis for auxiliary distinguishing coronavirus disease (COVID-19) by monitoring above indicators.
methodsA total of 84 patients with confirmed COVID-19 were enrolled in the study. Baseline characteristics and laboratory results were collected and analyzed. Receiver operating characteristic (ROC) curve analysis was used to combined detection of SAA and IL-6 in patients with COVID-19, and independent risk factors for severity of COVID-19 were assessed by using binary logistic regression.
resultsThe main clinical symptoms of patients with COVID-19 were fever (98.8%), fatigue (61.9%), and dry cough (58.3%). SAA, IL-6, and NLR were significantly higher in patients with COVID-19 (all P < .001), and compared with nonsevere patients, three indicators of severe patients were significantly elevated. Besides, combined detection of SAA and IL-6 better separates healthy people from patients with COVID-19 than detection of SAA or IL-6 alone. In addition, elevated SAA, IL-6, and NLR can be used as independent variables for predicting the severity of patients with COVID-19.
conclusionSerum amyloid A and IL-6 could be used as addition parameters to helping the distinguish of patients with COVID-19 from healthy people, and can provide potential basis for separating patients with nonsevere and severe clinical signs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.